Mitochondrial disease caused by point mutations in mitochondrial DMA (mtDNA) can be a formidable diagnostic challenge. Because clinical presentation can be variable, multisystemic, and mimic many other neurological disorders, ruling out an mtDNA etiology is difficult in patients with suspected myopathies or encephalopathies. DMA microarrays would seem to provide an ideal format for screening patient samples for the approximately200 mtDNA point mutations known or suspected to cause mitochondrial disease (Figure 1). When fabricated from conventional DNA oligonucleotides, however, microarrays often have inadequate power to discriminate, by hybridization, between mutant and wild-type DNAs that differ by a single base mismatch. This problem is aggravated for mtDNA mutations because they are present in most patients as a mixture of wild-type and mutant molecules - often as low as 10% in easily sampled material like peripheral blood. Oligonucleotides synthesized from Locked Nucleic Acid (LNA) nucleotides show much better mismatch detection. LNA-containing oligonucleotides in duplex with normal DNA have a remarkable combination of both high thermal stability (Tm) and enhanced Tm - i.e., the melting temperature difference between a perfect match and single base mismatch. Consequently, short probes (7-9 nt in length) can be used in arrays to maximize discriminatory power between mutant and wild-type DNAs while retaining efficient hybridization and, thus, sensitivity. Here, we propose to develop an array fabricated from LNA oligonucleotides for the detection of all 27 confirmed pathogenic point mutations in mtDNA. Its sensitivity for the detection of mtDNA mutations will be measured in samples containing a mixture of wild-type and mutant molecules. These studies will provide proof of principle for the successful design of an inclusive array to detect all reported pathogenic mtDNA mutations. As new ones are discovered, updated versions would be easy to generate. Towards this goal, the Specific Aims of this proposal are:
Specific Aim 1 : To develop capture probe pairs towards a set of 27 different mtDNA mutations.
Specific Aim 2 : To determine the performance of an optimized array to detect mtDNA mutations at varying frequencies.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ISD (01))
Program Officer
Preusch, Peter C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Geneprotech, Inc
St. Louis
United States
Zip Code
Barton, Christopher E; Tahinci, Emilios; Barbieri, Christopher E et al. (2009) DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Dev Biol 329:130-9
Barbieri, Christopher E; Tang, Luo Jia; Brown, Kimberly A et al. (2006) Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66:7589-97
Barbieri, Christopher E; Pietenpol, Jennifer A (2006) p63 and epithelial biology. Exp Cell Res 312:695-706
Barbieri, Christopher E; Perez, Carmen A; Johnson, Kimberly N et al. (2005) IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res 65:2314-20
Barbieri, Christopher E; Barton, Christopher E; Pietenpol, Jennifer A (2003) Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 278:51408-14